At the cutting edge of stroke research right here in France #ESOC2022! Here are nine things I learnt from nine trials today! #NeuroTwitter

¡Hola! Looking forward to learning about the latest advances in stroke research. See you soon in Barcelona! #WSC2025

#OpenAccess https://t.co/oTjsTQqAei

Emergency department presentations appear to be increasing in acuity in the state of Victoria, Australia. This rising urgency should prompt the health system to anticipate and prepare accordingly. @EMAJournal @VicGovDH

Victorian roads are becoming deadlier despite an overall reduction in road injury burden.

The contribution of clinical assistants to ED flow and length of stay #OpenAccess https://t.co/a93jQVijkb @ALim0211 @WileyHealth @acemonline

I've run the simulations and I believe we've discovered something interesting. Aspirin and #ticagrelor appears to be superior to aspirin and #clopidogrel for minor #stroke when clopidogrel resistance has not been excluded. https://t.co/DC31iTrLN5 @ClayJohnstonMD @GNtem1

🔴 Comparison of Dual Antiplatelet Therapies for Minor, Nondisabling, Acute Ischemic Stroke: https://t.co/dd338VSWCV #medtwitter #foamed #cardiology #CardioEd #CardioTwitter #Cardiogen #CVD #medtwitter #internalmedicine #hospitalist #meded #Medtwitter #Review #MedEd

✅DAPT w/ aspirin & ticagrelor has higher probability of being the superior Rx among pts w/ minor stroke w/n presence of CYP2C19 loss-of-function alleles has not been excluded. ✅For pts with TIA, superiority of aspirin & ticagrelor vs aspirin & clopidogrel was not demonstrated

Comparison of Dual Antiplatelet Therapies for Nondisabling Acute Ischemic Stroke https://t.co/VaUa3ff7Wz

Prof Shelagh Coutts announcing the results of the TEMPO-2 trial: no benefit and possibly harm in non-disabling minor stroke patients with intracranial occlusion treated with intravenous tenecteplase. #ESOC2024

Just announced in Basel, Switzerland! Thank you for listening to my talk! #ESOC2024

Bayesian analysis suggests that DAPT with aspirin + ticagrelor has higher probability of being the superior treatment among patients with minor stroke when presence of CYP2C19 loss-of-function alleles has not been excluded. https://t.co/DTssAsbebK @ALim0211 @GNtem1

Prof Xiong captivating the audience with TRACE III - tenecteplase reduced disability for Chinese patients with LVO 4.5-24h after onset with no safety concerns. #ESOC2024

The initial and the enduring impact of government lockdown and the pandemic on road injuries https://t.co/iFHnIH5kJX #OpenAccess @ALim0211 @WileyHealth @acemonline

"Road injury requiring hospitalisation decreased significantly during governmental lockdown & has returned to 3/4 of pre-pandemic levels (except bicyclist injuries that have remained constant) But there is an increasingly disproportionate number of fatalities."

Post‐lockdown burden of road injury involving hospitalisation in Victoria, Australia: A statewide, population‐based time series analysis - Lim - Emergency Medicine Australasia - Wiley Online Library

Congratulations to Dr. Andy Lim on your public disclosure, “Ninety‐Day Stroke Recurrence in Minor Stroke: Systematic Review and Meta‐Analysis of Trials and Observational Studies.” We’re proud to facilitate your access to data #ClinicalResearch https://t.co/JdmlIJLShR @MonashUni

@AshuPJadhav @ALim0211 Well done Andy. The pooled 90‐day stroke recurrence was 8.6% reducing by 0.60% with each subsequent year of publication. https://t.co/VLfaPhe13s @ClayJohnstonMD @mihill68

Ninety‐Day Stroke Recurrence in Minor Stroke: Systematic Review and Meta‐Analysis of Trials and Observational Studies | Journal of the American Heart Association

New Research: Rapid outpatient transient ischemic attack clinic and stroke service activity during the SARS-CoV-2 pandemic: a multicenter time series analysis: Background and aim Rapid outpatient evaluation and treatment of TIA in structured… https://t.co/AY4ddxJOJL #Neurology